Annual general meeting

Lassen Therapeutics Announces Oral Presentation of Phase I Data of LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Health, Oncology, Clinical Trials, Tissue, STAT3, Therapy, ATS, Annual Meetings of the International Monetary Fund and the World Bank Group, Cancer, Pharmacokinetics, Fibroblast, American Thoracic Society, Lung, Pulmonary fibrosis, Graves' ophthalmopathy, ERK, Annual general meeting, Idiopathic pulmonary fibrosis, TED, Pharmaceutical industry

In addition to the oral presentation at the Annual Meeting, Lassen has been invited to present at the ATS Respiratory Innovation Summit taking place on May 19, 2023.

Key Points: 
  • In addition to the oral presentation at the Annual Meeting, Lassen has been invited to present at the ATS Respiratory Innovation Summit taking place on May 19, 2023.
  • The presentation at ATS will further provide data demonstrating the fibro-inflammatory role of IL-11 in the lung and other tissues, and includes clinical pharmacokinetic and pharmacodynamic data for LASN01.
  • In the Phase I study, LASN01 exhibited dose-linear pharmacokinetics, with an excellent safety profile in healthy volunteers.
  • Dose-dependent inhibition of receptor signaling was demonstrated in a blood-based assay, demonstrating potent activity of the circulating antibody.

The Marcus Corporation Announces Postponement of 2023 Annual Shareholders' Meeting

Retrieved on: 
Tuesday, May 9, 2023
Entertainment, Other Entertainment, General Entertainment, Film & Motion Pictures, Lodging, Travel, COVID-19, Shareholder, Marcus Corporation, Health, The Pfister Hotel, MCS, NYSE, Safety, Annual general meeting, Private investigator, Birth control, Management

The Marcus Corporation (NYSE: MCS) today announced the Annual Meeting of Shareholders scheduled for Thursday, May 11, 2023, will be opened then immediately adjourned due to Stephen H. Marcus, chairman of The Marcus Corporation, and Gregory S. Marcus, president and chief executive officer of The Marcus Corporation, contracting mild cases of Covid and being unable to attend.

Key Points: 
  • The Marcus Corporation (NYSE: MCS) today announced the Annual Meeting of Shareholders scheduled for Thursday, May 11, 2023, will be opened then immediately adjourned due to Stephen H. Marcus, chairman of The Marcus Corporation, and Gregory S. Marcus, president and chief executive officer of The Marcus Corporation, contracting mild cases of Covid and being unable to attend.
  • To help ensure the health and safety of all participants, the full meeting is planned to be rescheduled for Tuesday, May 23, beginning at 9:00 a.m. Central/10:00 a.m. Eastern time at The Pfister Hotel, located at 424 East Wisconsin Avenue in Milwaukee.
  • Shareholders who planned to attend the meeting on Thursday, May 11 are encouraged to attend the full meeting, which is planned to occur on Tuesday, May 23 instead.

EIMA Announces Winners of EIFS Architectural Awards

Retrieved on: 
Tuesday, May 9, 2023
Built environment, Carbon, Wood, Annual general meeting, Industrial design

FALLS CHURCH, Va., May 9, 2023 /PRNewswire/ -- The EIFS Industry Members Association (EIMA) is pleased to announce the winners of the 2022 EIFS Architectural Awards .

Key Points: 
  • FALLS CHURCH, Va., May 9, 2023 /PRNewswire/ -- The EIFS Industry Members Association (EIMA) is pleased to announce the winners of the 2022 EIFS Architectural Awards .
  • Now in its fifth year, the EIFS Architectural Awards program has seen a total of 175 EIFS projects entered into the competition, the only of its kind specific to the EIFS industry.
  • The competition is judged by architects who are intimately familiar with the benefits of specifying EIFS, and all have been winners of EIFS Architectural Awards highest honors in the past.
  • The awards were presented during a ceremony held on April 26th at the 2023 EIMA Annual Meeting in Palm Springs, CA.

Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Tuesday, May 9, 2023
Abstract, University, Obstetrics, American Society of Clinical Oncology, New York University Grossman School of Medicine, Immunotherapy, ASCO, ALKS, H. Lee Moffitt Cancer Center & Research Institute, Patient, Clinical research, Annual general meeting, Gynaecology, Poster, CDT, Trial of the century, Pembrolizumab, Society, Medical imaging, Nursing, Management, Medicine

DUBLIN, May 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago June 2-6, 2023. Trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial will be presented. ARTISTRY-6 is evaluating nemvaleukin as a monotherapy in patients with advanced cutaneous melanoma or advanced mucosal melanoma. ARTISTRY-7 is evaluating nemvaleukin as a monotherapy and in combination with pembrolizumab in comparison to investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Key Points: 
  • DUBLIN, May 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago June 2-6, 2023.
  • Trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial will be presented.
  • ARTISTRY-6 is evaluating nemvaleukin as a monotherapy in patients with advanced cutaneous melanoma or advanced mucosal melanoma.
  • "The 2023 ASCO Annual Meeting provides a timely opportunity to engage with clinical trial investigators and share important information related to nemvaleukin and our potential registration-enabling clinical trials, ARTISTRY-6 and ARTISTRY-7," said Jessicca Rege, Vice President, Clinical Research, Oncology.

Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Tuesday, May 9, 2023
Abstract, University, Obstetrics, American Society of Clinical Oncology, New York University Grossman School of Medicine, Immunotherapy, ASCO, ALKS, H. Lee Moffitt Cancer Center & Research Institute, Patient, Clinical research, Annual general meeting, Gynaecology, Poster, CDT, Trial of the century, Pembrolizumab, Society, Medical imaging, Nursing, Management, Medicine

DUBLIN, May 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago June 2-6, 2023. Trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial will be presented. ARTISTRY-6 is evaluating nemvaleukin as a monotherapy in patients with advanced cutaneous melanoma or advanced mucosal melanoma. ARTISTRY-7 is evaluating nemvaleukin as a monotherapy and in combination with pembrolizumab in comparison to investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Key Points: 
  • DUBLIN, May 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago June 2-6, 2023.
  • Trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial will be presented.
  • ARTISTRY-6 is evaluating nemvaleukin as a monotherapy in patients with advanced cutaneous melanoma or advanced mucosal melanoma.
  • "The 2023 ASCO Annual Meeting provides a timely opportunity to engage with clinical trial investigators and share important information related to nemvaleukin and our potential registration-enabling clinical trials, ARTISTRY-6 and ARTISTRY-7," said Jessicca Rege, Vice President, Clinical Research, Oncology.

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, May 9, 2023
PK, SDMA, MTAP, AACR, GBM, Repressor, MTA, Bone marrow suppression, Therapeutic index, Clinical trial, Pharmacokinetics, Mutation, Traffic barrier, Histology, Fast Track, Breast, NSCLC, STK11, Carcinoma, Tango, Glioblastoma, PRMT5, Research and development, RCOR1, American Association for Cancer Research, Patient, Cancer, Annual general meeting, Neoplasm, Infrared spectroscopy correlation table, FDA, Pembrolizumab, Collaboration, Therapy, IND, FTD, Safety, Pharmaceutical industry, Vaccine, Research

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.

Key Points: 
  • We look forward to providing additional data from the trial in 2024,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics.
  • TNG908 proof-of-mechanism as an MTA-cooperative PRMT5 inhibitor demonstrated by marked SDMA reduction in MTAP-deleted cancer cells versus normal tissue.
  • The TNG462 Investigational New Drug (IND) application cleared in January 2023, and the first patient is expected to be dosed in mid-2023.
  • General and administrative expenses were $8.0 million for the three months ended March 31, 2023, compared to $6.8 million for the same period in 2022.

Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results

Retrieved on: 
Tuesday, May 9, 2023
GBA1, Telephone, Neurocrine Biosciences, Neurocrine, TRACER, G&A, Huntington's disease, Cell, Toxicology, ALS, Neurology, DSM-IV codes, Gene, HTT, Disease, Research, Brain, SOD1, FXN, Sirna Therapeutics, Growth, FDA, IND, Conference, VY, D, Exercise, GLP, Biotechnology, Conference call, Therapy, HD, Central nervous system, Capsid, Doctor of Philosophy, Ataxia, Traffic barrier, CNS, MSH3, Annual general meeting, Mouse, AD, Society, Pharmaceutical industry, Vaccine, Voyager, Novartis

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported first quarter 2023 financial and operating results.

Key Points: 
  • ET today -
    CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported first quarter 2023 financial and operating results.
  • In March 2023, Voyager presented new data at the AD/PD 2023 Conference highlighting the differentiating characteristics resulting in the selection of VY-TAU01.
  • Early data were presented at the 18th Annual Huntington's Disease Therapeutics Conference held in Zagreb, Croatia, April 24 – 27, 2023.
  • ET to discuss the first quarter 2023 financial and operating results.

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
PK, Journal of Clinical Oncology, Abstract, PD, Anticipation, Pharming, Cancer, G&A, NK, Cell, Part, IL-2, ASCO, Journal, American Society of Clinical Oncology, Patient, Administration, Melanoma, Annual general meeting, TME, R, Therapy, Tumor microenvironment, Society, FC, Safety, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency

WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Xilio anticipates reporting preliminary anti-tumor activity, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from the Phase 1/2 clinical trial in the third quarter of 2023.
  • Xilio anticipates reporting preliminary safety data from the Phase 1 clinical trial into at least the third dose level in the fourth quarter of 2023.
  • Xilio plans to report additional preliminary Phase 1 safety, PK, PD, and anti-tumor activity data by the end of the second quarter of 2023.
  • Net Loss: Net loss was $22.6 million for the quarter ended March 31, 2023, compared to $21.4 million for the quarter ended March 31, 2022.

ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting

Retrieved on: 
Tuesday, May 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Abstract, CT, Senior, Fallopian tube cancer, Overalls, Survival, Cancer, Fallopian tube, Gynecologic Oncology (journal), Peritonitis, ImmunoGen, Mirvetuximab soravtansine, IMGN, Associate, ASCO, Bevacizumab, American Society of Clinical Oncology, MD, Patient, University, Randomness, Clinical research, University of Oklahoma, Annual general meeting, Spacecraft, GOG, Society, Safety, Birth control, Maintenance

"We are honored that MIRASOL has been selected as a late-breaker presentation at ASCO, and pleased that we will be able to share the results from the trial so quickly after they became available," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen.

Key Points: 
  • "We are honored that MIRASOL has been selected as a late-breaker presentation at ASCO, and pleased that we will be able to share the results from the trial so quickly after they became available," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen.
  • "Having demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to investigator's choice of single-agent chemotherapy, I believe ELAHERE has the potential to be practice changing in FRα-positive, platinum-resistant ovarian cancer."
  • Title: Phase III MIRASOL (GOG 3045/ENGOT-ov55) Study: Initial Report of Mirvetuximab Soravtansine vs.
  • ImmunoGen will present two additional trial-in-progress posters at ASCO.

Ventas Reports 2023 First Quarter Results

Retrieved on: 
Monday, May 8, 2023
Managed Care, General Health, Consumer, Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Hospitals, Construction & Property, Nursing, Seniors, REIT, Health, Ardent Health Services, U.S. Department of Energy, Office of Inspector General, Office of Inspector General, U.S. Department of Health and Human Services, HHS, Event, Debt-to-GDP ratio, CAD, SOFR, Woman, GAAP, Committee, Central Time, Sale, Santerre, Ardent, Health care, Partner, Annual general meeting, Biophysical environment, NOI, Depreciation, Social, Comparison of multi-paradigm programming languages, NYSE, Security (finance), Bookkeeping, Ventas, Normalization

In the first quarter, the Company executed $400 million in fixed pay 2-year SOFR swaps at an all-in weighted average rate of 3.79%.

Key Points: 
  • In the first quarter, the Company executed $400 million in fixed pay 2-year SOFR swaps at an all-in weighted average rate of 3.79%.
  • As a result, Ventas improved its floating rate debt exposure to 10.5% of total consolidated debt as of March 31.
  • Additional information regarding the Company can be found in its first quarter 2023 supplemental posted at ir.ventasreit.com.
  • Ventas will hold a conference call to discuss this earnings release on Tuesday, May 9, 2023 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time).